Ahn Y S, Harrington W J
Annu Rev Med. 1977;28:299-309ENG. doi: 10.1146/annurev.me.28.020177.001503.
In summary, idiopathic thrombocytopenic purpura (as defined here) should be treated initially with glucocorticoids unless there is life-threatening hemorrhage (such as intracranial bleeding), in which case emergency splenectomy is indicated, since it generally gives the most prompt improvement in platelet count of all modes of the disease and to better define the cause of the thrombocytopenia. A complete, sustained remission following treatment with steroids may occasionally be obtained. In most cases the steroid response is transient, and splenectomy is the most definitive measure with respect to a lifelong cure. Complete clinical cure is obtained in 70-80% of instances following splenectomy, with a very low operative risk. The remainder either fail to respond or experience relapse. In this group of patients steroids should again be tried; if a good response is obtained, steroids should be given every second or third day to lessen long-term side effects. If these measures fail, the use of immunosuppressive agents is justified. Both vinca alkaloids and cyclophosphamide are especially useful. Vinca alkaloids act more promptly, but cyclophosphamide may have a more lasting effect. Azathioprine may also be used; however, it appears to yield a lower remission rate. Nonsteroidal immunosuppressive agents should not be used as the primary modality of therapy. And, due to their carcinogenic and teratogenic potential, they should be avoided, if possible, especially in children and in women during their childbearing years.
总之,特发性血小板减少性紫癜(如本文所定义)最初应以糖皮质激素治疗,除非存在危及生命的出血(如颅内出血),在这种情况下应进行急诊脾切除术,因为它通常能使血小板计数在所有治疗方式中得到最迅速的改善,并且有助于更好地明确血小板减少的原因。使用类固醇治疗后偶尔可获得完全、持续的缓解。在大多数情况下,类固醇反应是短暂的,脾切除术是实现终身治愈的最确切措施。脾切除术后70 - 80%的病例可实现完全临床治愈,手术风险极低。其余患者要么无反应,要么复发。对于这组患者,应再次尝试使用类固醇;如果获得良好反应,应每隔一天或两天给予类固醇以减轻长期副作用。如果这些措施失败,则有理由使用免疫抑制剂。长春花生物碱和环磷酰胺都特别有用。长春花生物碱起效更快,但环磷酰胺可能有更持久的效果。也可使用硫唑嘌呤;然而,其缓解率似乎较低。非甾体类免疫抑制剂不应作为主要治疗方式。并且,由于其致癌和致畸潜力,应尽可能避免使用,尤其是在儿童和育龄妇女中。